Morgan Stanley on Vertex (VRTX): 'Exa-cel filing timeline better than feared'

September 27, 2022 10:15 AM EDT Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $253.00 price target on Vertex (NASDAQ: VRTX).The analyst comments "Exa-cel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login